Celsion Stock Price, News & Analysis (NASDAQ:CLSN)

$2.80 -0.01 (-0.36 %)
(As of 12/15/2017 06:51 AM ET)
Previous Close$2.81
Today's Range$2.70 - $2.84
52-Week Range$1.24 - $8.82
Volume453,600 shs
Average Volume1.60 million shs
Market Capitalization$45.13 million
P/E RatioN/A
Dividend YieldN/A
Beta1.22

About Celsion (NASDAQ:CLSN)

Celsion logoCelsion Corporation is an oncology drug development company. The Company's product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study). Its pipeline also includes GEN-1, a deoxyribonucleic acid (DNA) mediated immunotherapy for the localized treatment of ovarian and brain cancers. It has over three platform technologies for the development of treatments for those suffering with difficult-to-treat forms of cancer, including Lysolipid Thermally Sensitive Liposomes, a heat sensitive liposomal based dosage form that targets disease with known therapeutics in the presence of mild heat; TheraPlas, a nucleic acid-based treatment for local transfection of therapeutic plasmids, and TheraSilence, a systemic dosage form for lung directed anti-cancer ribonucleic acid (RNA).

Receive CLSN News and Ratings via Email

Sign-up to receive the latest news and ratings for CLSN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CLSN
CUSIPN/A
Phone609-896-9100

Debt

Debt-to-Equity RatioN/A
Current Ratio0.46%
Quick Ratio0.46%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$500,000.00
Price / Sales89.94
Cash FlowN/A
Price / CashN/A
Book Value$3.01 per share
Price / Book0.93

Profitability

Trailing EPS($5.83)
Net Income$-22,050,000.00
Net Margins-4,292.80%
Return on Equity-282.94%
Return on Assets-59.69%

Miscellaneous

Employees19
Outstanding Shares16,060,000

Celsion (NASDAQ:CLSN) Frequently Asked Questions

What is Celsion's stock symbol?

Celsion trades on the NASDAQ under the ticker symbol "CLSN."

When did Celsion's stock split? How did Celsion's stock split work?

Celsion shares reverse split on Tuesday, May 30th 2017. The 1-14 reverse split was announced on Friday, May 26th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 26th 2017. An investor that had 100 shares of Celsion stock prior to the reverse split would have 7 shares after the split.

How were Celsion's earnings last quarter?

Celsion Co. (NASDAQ:CLSN) released its quarterly earnings data on Thursday, May, 18th. The biotechnology company reported ($1.64) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($1.30) by $0.34. The biotechnology company had revenue of $0.13 million for the quarter, compared to analyst estimates of $0.13 million. Celsion had a negative return on equity of 282.94% and a negative net margin of 4,292.80%. View Celsion's Earnings History.

When will Celsion make its next earnings announcement?

Celsion is scheduled to release their next quarterly earnings announcement on Thursday, March, 15th 2018. View Earnings Estimates for Celsion.

Where is Celsion's stock going? Where will Celsion's stock price be in 2017?

4 brokerages have issued 1-year target prices for Celsion's stock. Their predictions range from $7.00 to $21.00. On average, they anticipate Celsion's stock price to reach $14.50 in the next year. View Analyst Ratings for Celsion.

What are Wall Street analysts saying about Celsion stock?

Here are some recent quotes from research analysts about Celsion stock:

  • 1. According to Zacks Investment Research, "Celsion is dedicated to the development and commercialization of oncology drugs including tumor-targeting treatments using focused heat energy in combination with heat activated drug delivery systems. Celsion has research, license or commercialization agreements with leading institutions such as the National Institutes of Health, Duke University Medical Center, University of Hong Kong, North Shore Long Island Jewish Health System. " (10/17/2017)
  • 2. Maxim Group analysts commented, "Celsion announced that the company will present updated data from the P1b Ovation study evaluating GEN-1 (DNA-based IL-12) in advanced ovarian cancer at ASCO (American Society of Clinical Oncology, June 2-6, 2017)." (4/20/2017)

Are investors shorting Celsion?

Celsion saw a increase in short interest during the month of November. As of November 30th, there was short interest totalling 1,719,534 shares, an increase of 44.0% from the November 15th total of 1,193,756 shares. Based on an average daily volume of 5,485,704 shares, the days-to-cover ratio is presently 0.3 days. Currently, 10.8% of the shares of the stock are sold short.

Who are some of Celsion's key competitors?

Who are Celsion's key executives?

Celsion's management team includes the folowing people:

  • Jeffrey Wayne Church CPA, Chief Financial Officer, Senior Vice President, Corporate Secretary, IR Contact Officer (Age 58)
  • Khursheed Anwer Ph.D., Executive Vice President, Chief Scientific Officer - Nucleic Acid Therapy (Age 55)
  • Nicholas Borys M.D., Senior Vice President and Chief Medical Officer (Age 55)
  • Michael H. Tardugno, Executive Chairman of the Board, President, Chief Executive Officer (Age 64)
  • Donald Braun Ph.D., Independent Director
  • Pok Yu Chow Ph.D., Independent Director (Age 63)
  • Frederick J. Fritz, Independent Director (Age 64)
  • Robert W. Hooper, Independent Director (Age 68)
  • Alberto R. Martinez M.D., Independent Director (Age 65)

Who owns Celsion stock?

Celsion's stock is owned by a variety of of institutional and retail investors. Top institutional investors include INTRACOASTAL CAPITAL, LLC (0.03%). Company insiders that own Celsion stock include Alberto R Martinez Jr, Frederick J Fritz and Michael H Tardugno. View Institutional Ownership Trends for Celsion.

How do I buy Celsion stock?

Shares of Celsion can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Celsion's stock price today?

One share of Celsion stock can currently be purchased for approximately $2.80.

How big of a company is Celsion?

Celsion has a market capitalization of $45.13 million and generates $500,000.00 in revenue each year. The biotechnology company earns $-22,050,000.00 in net income (profit) each year or ($5.83) on an earnings per share basis. Celsion employs 19 workers across the globe.

How can I contact Celsion?

Celsion's mailing address is 997 LENOX DRIVE, LAWRENCEVILLE NJ, 08648. The biotechnology company can be reached via phone at 609-896-9100 or via email at [email protected]


MarketBeat Community Rating for Celsion (CLSN)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  215 (Vote Outperform)
Underperform Votes:  126 (Vote Underperform)
Total Votes:  341
MarketBeat's community ratings are surveys of what our community members think about Celsion and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Celsion (NASDAQ:CLSN) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.002.672.67
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $14.50$16.33$32.67$32.67
Price Target Upside: 577.57% upside169.53% upside2,137.44% upside1,096.58% upside

Celsion (NASDAQ:CLSN) Consensus Price Target History

Price Target History for Celsion (NASDAQ:CLSN)

Celsion (NASDAQ:CLSN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/21/2017OppenheimerInitiated CoverageOutperform$9.00N/AView Rating Details
10/4/2017Maxim GroupUpgradeHold -> Buy$7.00HighView Rating Details
4/10/2017Rodman & RenshawReiterated RatingBuy$21.00HighView Rating Details
4/10/2017HC WainwrightReiterated RatingBuy$21.00HighView Rating Details
(Data available from 12/15/2015 forward)

Earnings

Celsion (NASDAQ:CLSN) Earnings History and Estimates Chart

Earnings by Quarter for Celsion (NASDAQ:CLSN)

Celsion (NASDAQ CLSN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/15/2018        
5/18/2017Q1 2017($1.30)($1.64)$0.13 million$0.13 millionViewN/AView Earnings Details
3/16/2017Q4 2016($2.24)($1.96)$0.13 million$0.13 millionViewN/AView Earnings Details
11/10/2016Q3 2016($2.66)($3.22)$0.13 million$0.13 millionViewN/AView Earnings Details
8/15/2016Q2($2.94)($2.66)$0.13 million$0.13 millionViewListenView Earnings Details
5/16/2016Q116($2.94)($3.36)$0.13 million$0.13 millionViewListenView Earnings Details
3/30/2016Q415($3.36)($3.36)$0.16 million$0.13 millionViewListenView Earnings Details
11/5/2015Q315($3.64)($2.80)$0.14 million$0.13 millionViewN/AView Earnings Details
8/10/2015Q215($4.34)($3.78)$0.16 million$0.13 millionViewListenView Earnings Details
5/12/2015Q1($4.62)($4.76)$0.13 million$0.13 millionViewN/AView Earnings Details
3/12/2015Q4 2014($5.04)($4.48)$0.13 million$0.13 millionViewN/AView Earnings Details
11/11/2014Q3 2014($4.20)($4.90)$0.16 million$0.13 millionViewN/AView Earnings Details
8/7/2014Q214($3.92)($4.48)$0.13 million$0.13 millionViewN/AView Earnings Details
5/8/2014Q1 2014($2.80)($4.62)$0.13 million$0.13 millionViewN/AView Earnings Details
3/13/2014($3.92)($2.66)ViewN/AView Earnings Details
11/12/2013Q3($3.15)($4.20)$0.13 millionViewListenView Earnings Details
8/8/2013Q2 2013($0.98)$0.14$0.13 millionViewN/AView Earnings Details
5/9/2013Q1 2013($2.24)($1.68)ViewN/AView Earnings Details
11/12/2012Q312($2.38)($2.52)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Celsion (NASDAQ:CLSN) Earnings Estimates

2017 EPS Consensus Estimate: ($1.05)
2018 EPS Consensus Estimate: ($1.44)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.08)($0.08)($0.08)
Q2 20171($0.08)($0.08)($0.08)
Q3 20171($0.56)($0.56)($0.56)
Q4 20172($0.37)($0.29)($0.33)
Q1 20181($0.37)($0.37)($0.37)
Q2 20181($0.39)($0.39)($0.39)
Q3 20181($0.38)($0.38)($0.38)
Q4 20181($0.30)($0.30)($0.30)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Celsion (NASDAQ:CLSN)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Celsion (NASDAQ CLSN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.80%
Institutional Ownership Percentage: 4.15%
Insider Trades by Quarter for Celsion (NASDAQ:CLSN)
Institutional Ownership by Quarter for Celsion (NASDAQ:CLSN)

Celsion (NASDAQ CLSN) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/7/2017Frederick J FritzDirectorBuy13,000$1.89$24,570.00View SEC Filing  
2/21/2017Alberto R Martinez JrDirectorBuy35,000$0.23$8,050.00View SEC Filing  
2/15/2017Alberto R Martinez JrDirectorBuy45,000$0.22$9,900.00View SEC Filing  
11/14/2016Alberto R Martinez JrDirectorBuy10,000$0.86$8,600.00View SEC Filing  
11/11/2016Alberto R Martinez JrDirectorBuy10,000$0.91$9,100.00View SEC Filing  
10/7/2016Michael H TardugnoChairmanBuy10,000$1.14$11,400.00View SEC Filing  
8/16/2016Alberto R Martinez JrDirectorBuy5,000$1.25$6,250.00View SEC Filing  
6/17/2016Alberto R Martinez JrDirectorBuy5,000$1.35$6,750.00View SEC Filing  
6/16/2016Michael H TardugnoCEOBuy7,500$1.35$10,125.00View SEC Filing  
2/19/2016Michael H TardugnoCEOBuy3,000$1.27$3,810.00View SEC Filing  
2/17/2016Michael H TardugnoCEOBuy2,000$1.27$2,540.00View SEC Filing  
2/16/2016Alberto R Martinez JrDirectorBuy5,000$1.16$5,800.00View SEC Filing  
2/16/2016Michael H TardugnoCEOBuy4,500$1.20$5,400.00View SEC Filing  
2/12/2016Michael H TardugnoCEOBuy6,500$1.13$7,345.00View SEC Filing  
12/3/2015Egwu, Inc. Fka Egen, Inc.Major ShareholderSell5,556$2.08$11,556.48View SEC Filing  
11/30/2015Egwu, Inc. Fka Egen, Inc.Major ShareholderSell20,000$2.15$43,000.00View SEC Filing  
9/8/2015Egwu, Inc. Fka Egen, Inc.Major ShareholderSell10,000$2.11$21,100.00View SEC Filing  
8/17/2015Egwu, Inc. Fka Egen, Inc.Major ShareholderSell10,000$2.19$21,900.00View SEC Filing  
8/13/2015Egwu, Inc. Fka Egen, Inc.Major ShareholderSell20,000$2.23$44,600.00View SEC Filing  
5/13/2015Alberto R Martinez JrDirectorBuy5,000$2.50$12,500.00View SEC Filing  
12/18/2014Frederick J FritzDirectorBuy4,000$2.34$9,360.00View SEC Filing  
11/13/2014Robert W HooperDirectorBuy4,000$2.50$10,000.00View SEC Filing  
8/15/2014Alberto R Martinez JrDirectorBuy5,000$3.12$15,600.00View SEC Filing  
8/15/2014Michael H TardugnoCEOBuy4,000$3.12$12,480.00View SEC Filing  
8/14/2014Frederick J FritzDirectorBuy4,000$3.20$12,800.00View SEC Filing  
6/26/2014Alberto R Martinez JrDirectorBuy5,000$3.36$16,800.00View SEC Filing  
6/11/2014Michael H TardugnoCEOBuy5,000$3.20$16,000.00View SEC Filing  
3/14/2014Frederick FritzDirectorBuy2,500$3.86$9,650.00View SEC Filing  
3/14/2014Michael TardugnoCEOBuy4,000$3.84$15,360.00View SEC Filing  
11/19/2013Michael TardugnoCEOBuy2,800$3.59$10,052.00View SEC Filing  
11/15/2013Frederick FritzDirectorBuy3,000$3.80$11,400.00View SEC Filing  
8/16/2013Frederick FritzDirectorBuy10,000$1.09$10,900.00View SEC Filing  
8/16/2013Michael TardugnoCEOBuy5,000$1.08$5,400.00View SEC Filing  
6/12/2013Michael H TardugnoCEOBuy10,000$1.35$13,500.00View SEC Filing  
5/21/2013Alberto R Martinez JrDirectorBuy5,000$0.93$4,650.00View SEC Filing  
5/13/2013Alberto R Martinez JrDirectorBuy5,000$0.96$4,800.00View SEC Filing  
5/10/2013Alberto R Martinez JrDirectorBuy5,000$0.92$4,600.00View SEC Filing  
3/20/2013Alberto R Martinez JrDirectorBuy3,750$1.06$3,975.00View SEC Filing  
12/10/2012Max LinkDirectorBuy14,000$7.60$106,400.00View SEC Filing  
11/15/2012Robert W HooperDirectorBuy11,600$5.20$60,320.00View SEC Filing  
9/14/2012Michael H TardugnoCEOBuy5,000$5.03$25,150.00View SEC Filing  
9/10/2012Robert W HooperDirectorBuy10,000$4.95$49,500.00View SEC Filing  
8/29/2012Robert W HooperDirectorBuy2,500$4.65$11,625.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Celsion (NASDAQ CLSN) News Headlines

Source:
DateHeadline
Celsion Co. (CLSN) Short Interest UpdateCelsion Co. (CLSN) Short Interest Update
www.americanbankingnews.com - December 15 at 3:08 AM
Financial Review: Celsion (CLSN) vs. The CompetitionFinancial Review: Celsion (CLSN) vs. The Competition
www.americanbankingnews.com - December 11 at 11:22 PM
ETFs with exposure to Celsion Corp. : December 11, 2017ETFs with exposure to Celsion Corp. : December 11, 2017
finance.yahoo.com - December 11 at 5:19 PM
Celsion (CLSN) Upgraded to "Sell" at ValuEngineCelsion (CLSN) Upgraded to "Sell" at ValuEngine
www.americanbankingnews.com - December 9 at 12:08 PM
Adaptimmune Therapeutics (ADAP) & Celsion (CLSN) Critical ContrastAdaptimmune Therapeutics (ADAP) & Celsion (CLSN) Critical Contrast
www.americanbankingnews.com - December 9 at 5:30 AM
Comparing Celsion (CLSN) & Its RivalsComparing Celsion (CLSN) & Its Rivals
www.americanbankingnews.com - December 5 at 11:30 AM
ETFs with exposure to Celsion Corp. : November 30, 2017ETFs with exposure to Celsion Corp. : November 30, 2017
finance.yahoo.com - November 30 at 5:04 PM
Celsion Corp. :CLSN-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017Celsion Corp. :CLSN-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017
finance.yahoo.com - November 29 at 9:50 AM
Celsion Corporation (CLSN) Short Interest UpdateCelsion Corporation (CLSN) Short Interest Update
www.americanbankingnews.com - November 29 at 2:08 AM
Celsion Delivering Doxorubicin To Cancer TissuesCelsion Delivering Doxorubicin To Cancer Tissues
seekingalpha.com - November 23 at 4:02 PM
Brokers Offer Predictions for Celsion Corporations Q4 2017 Earnings (CLSN)Brokers Offer Predictions for Celsion Corporation's Q4 2017 Earnings (CLSN)
www.americanbankingnews.com - November 23 at 9:58 AM
Celsion builds on up move ahead of ThermoDox study data; shares ahead 20% after hours - Seeking AlphaCelsion builds on up move ahead of ThermoDox study data; shares ahead 20% after hours - Seeking Alpha
seekingalpha.com - November 21 at 10:26 PM
Why Celsion Could Still More Than Double on Top of Good NewsWhy Celsion Could Still More Than Double on Top of Good News
247wallst.com - November 21 at 5:26 PM
Here’s Why Celsion Corporation Draws a Vote of Confidence from OppenheimerHere’s Why Celsion Corporation Draws a Vote of Confidence from Oppenheimer
finance.yahoo.com - November 21 at 5:26 PM
Celsion Corporation (CLSN) Given Average Recommendation of "Buy" by AnalystsCelsion Corporation (CLSN) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - November 21 at 3:38 PM
Celsion Corporation (CLSN) Now Covered by Oppenheimer Holdings, Inc.Celsion Corporation (CLSN) Now Covered by Oppenheimer Holdings, Inc.
www.americanbankingnews.com - November 21 at 2:38 PM
Celsion (CLSN) Reports Publication of the Study of ThermoDox and Ultrasound in the Journal of Therapeutic Ultrasound - StreetInsider.comCelsion (CLSN) Reports Publication of the Study of ThermoDox and Ultrasound in the Journal of Therapeutic Ultrasound - StreetInsider.com
www.streetinsider.com - November 21 at 4:25 AM
Celsion (CLSN) Reports Publication of the Study of ThermoDox and Ultrasound in the Journal of Therapeutic UltrasoundCelsion (CLSN) Reports Publication of the Study of ThermoDox and Ultrasound in the Journal of Therapeutic Ultrasound
www.streetinsider.com - November 20 at 6:23 PM
Celsion Announces Publication of the Study of ThermoDox® + Ultrasound, “TARDOX Study Protocol” in the Journal of Therapeutic UltrasoundCelsion Announces Publication of the Study of ThermoDox® + Ultrasound, “TARDOX Study Protocol” in the Journal of Therapeutic Ultrasound
finance.yahoo.com - November 20 at 6:23 PM
Celsion Corporation (CLSN) Shares Climb on Back of New Findings in Liver Tumours StudyCelsion Corporation (CLSN) Shares Climb on Back of New Findings in Liver Tumours Study
finance.yahoo.com - November 20 at 6:23 PM
Reviewing Relypsa (RLYP) and Celsion Corporation (CLSN)Reviewing Relypsa (RLYP) and Celsion Corporation (CLSN)
www.americanbankingnews.com - November 19 at 5:34 PM
Celsion Corporation (CLSN) Cut to "Strong Sell" at ValuEngineCelsion Corporation (CLSN) Cut to "Strong Sell" at ValuEngine
www.americanbankingnews.com - November 15 at 10:56 PM
Celsion (CLSN) Files Immunotherapy Clinical Protocol for Evaluation of GEN-1 to Treat Newly Diagnosed Ovarian ... - StreetInsider.comCelsion (CLSN) Files Immunotherapy Clinical Protocol for Evaluation of GEN-1 to Treat Newly Diagnosed Ovarian ... - StreetInsider.com
www.streetinsider.com - November 15 at 12:13 AM
Celsion Corporation Reports Third Quarter 2017 Financial Results and Provides Business Update - GlobeNewswire (press release)Celsion Corporation Reports Third Quarter 2017 Financial Results and Provides Business Update - GlobeNewswire (press release)
globenewswire.com - November 15 at 12:13 AM
Edited Transcript of CLSN earnings conference call or presentation 14-Nov-17 4:00pm GMTEdited Transcript of CLSN earnings conference call or presentation 14-Nov-17 4:00pm GMT
finance.yahoo.com - November 15 at 12:13 AM
Celsion Corporation to Host Earnings CallCelsion Corporation to Host Earnings Call
finance.yahoo.com - November 14 at 5:48 PM
Celsion Corporation Reports Third Quarter 2017 Financial Results and Provides Business UpdateCelsion Corporation Reports Third Quarter 2017 Financial Results and Provides Business Update
finance.yahoo.com - November 14 at 5:48 PM
Today’s Research Reports on Stocks to Watch: Celsion Corporation and Nektar TherapeuticsToday’s Research Reports on Stocks to Watch: Celsion Corporation and Nektar Therapeutics
finance.yahoo.com - November 14 at 5:48 PM
Is It The Right Time To Buy Celsion Corporation (CLSN)?Is It The Right Time To Buy Celsion Corporation (CLSN)?
finance.yahoo.com - November 14 at 5:48 PM
Celsion Corporation (CLSN) Announces Quarterly  Earnings Results, Misses Expectations By $0.14 EPSCelsion Corporation (CLSN) Announces Quarterly Earnings Results, Misses Expectations By $0.14 EPS
www.americanbankingnews.com - November 14 at 9:12 AM
Celsion Files Immunotherapy Clinical Protocol for the Evaluation of GEN-1 to Treat Newly Diagnosed Ovarian CancerCelsion Files Immunotherapy Clinical Protocol for the Evaluation of GEN-1 to Treat Newly Diagnosed Ovarian Cancer
finance.yahoo.com - November 13 at 10:37 PM
CORRECTING and REPLACING -- Celsion Files Immunotherapy Clinical Protocol for the Evaluation of GEN-1 to Treat Newly Diagnosed Ovarian CancerCORRECTING and REPLACING -- Celsion Files Immunotherapy Clinical Protocol for the Evaluation of GEN-1 to Treat Newly Diagnosed Ovarian Cancer
finance.yahoo.com - November 13 at 10:37 PM
Celsion Corporation (CLSN) Short Interest Down 57.6% in OctoberCelsion Corporation (CLSN) Short Interest Down 57.6% in October
www.americanbankingnews.com - November 13 at 2:32 AM
Celsion Corporation (CLSN) Set to Announce Quarterly Earnings on TuesdayCelsion Corporation (CLSN) Set to Announce Quarterly Earnings on Tuesday
www.americanbankingnews.com - November 8 at 10:14 AM
Celsion Corporation to Hold Third Quarter 2017 Financial Results Conference Call on Tuesday, November 14, 2017 - GlobeNewswire (press release)Celsion Corporation to Hold Third Quarter 2017 Financial Results Conference Call on Tuesday, November 14, 2017 - GlobeNewswire (press release)
globenewswire.com - November 7 at 10:20 PM
ETFs with exposure to Celsion Corp. : November 7, 2017ETFs with exposure to Celsion Corp. : November 7, 2017
finance.yahoo.com - November 7 at 10:20 PM
Celsion Corporation to Hold Third Quarter 2017 Financial Results Conference Call on Tuesday, November 14, 2017Celsion Corporation to Hold Third Quarter 2017 Financial Results Conference Call on Tuesday, November 14, 2017
feeds.benzinga.com - November 7 at 10:07 AM
Celsion Corporation Announces Pricing of Underwritten Offering of ... - GlobeNewswire (press release)Celsion Corporation Announces Pricing of Underwritten Offering of ... - GlobeNewswire (press release)
globenewswire.com - October 29 at 3:36 AM
Celsion (CLSN) Prices Offering of Common Stock and Warrants - StreetInsider.comCelsion (CLSN) Prices Offering of Common Stock and Warrants - StreetInsider.com
www.streetinsider.com - October 28 at 1:04 AM
Celsion (CLSN) Prices Offering of Common Stock and WarrantsCelsion (CLSN) Prices Offering of Common Stock and Warrants
www.streetinsider.com - October 27 at 8:03 PM
Celsion Corporation Announces Pricing of Underwritten Offering of Common Stock and Warrants to Purchase Common StockCelsion Corporation Announces Pricing of Underwritten Offering of Common Stock and Warrants to Purchase Common Stock
finance.yahoo.com - October 27 at 8:03 PM
Celsion Corporation (CLSN) Spooks Investors with a Share DilutionCelsion Corporation (CLSN) Spooks Investors with a Share Dilution
finance.yahoo.com - October 27 at 8:03 PM
Short Interest in Celsion Corporation (CLSN) Grows By 88.9%Short Interest in Celsion Corporation (CLSN) Grows By 88.9%
www.americanbankingnews.com - October 27 at 1:40 AM
Celsion Corporation (CLSN) to Post Q3 2017 Earnings of ($0.56) Per Share, Griffin Securities ForecastsCelsion Corporation (CLSN) to Post Q3 2017 Earnings of ($0.56) Per Share, Griffin Securities Forecasts
www.americanbankingnews.com - October 20 at 9:00 AM
Celsion Provides Summary of Research and Development Day Held on October 12, 2017Celsion Provides Summary of Research and Development Day Held on October 12, 2017
feeds.benzinga.com - October 18 at 8:55 AM
Celsion Co. (CLSN) Stock Rating Lowered by Zacks Investment ResearchCelsion Co. (CLSN) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - October 17 at 8:26 PM
Celsion Provides Summary of Research and Development Day Held on Thursday, October 12, 2017Celsion Provides Summary of Research and Development Day Held on Thursday, October 12, 2017
finance.yahoo.com - October 17 at 6:04 PM
Celsion Announces Publication of the HEAT Study Manuscript in the High Impact Journal, Clinical Cancer ResearchCelsion Announces Publication of the HEAT Study Manuscript in the High Impact Journal, Clinical Cancer Research
finance.yahoo.com - October 16 at 6:01 PM
Celsion to Host Research and Development (R&D) Day on Thursday, October 12, 2017Celsion to Host Research and Development (R&D) Day on Thursday, October 12, 2017
finance.yahoo.com - October 12 at 6:05 PM
ETFs with exposure to Celsion Corp. : October 10, 2017ETFs with exposure to Celsion Corp. : October 10, 2017
finance.yahoo.com - October 10 at 6:28 PM

SEC Filings

Celsion (NASDAQ:CLSN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Celsion (NASDAQ:CLSN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Celsion (NASDAQ CLSN) Stock Chart for Friday, December, 15, 2017

Loading chart…

This page was last updated on 12/15/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.